8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Mar 26, 2026·SEC
SANUWAVE Health, Inc.(SNWV)Earnings, Financials & Key Ratios
SNWV•NASDAQ
22.5× P/E·Price updated Jun 19, 2026
AboutSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.Show more
- Revenue$44M+35.0%
- EBITDA$6M-5.1%
- Net Income$12M+137.7%
- EPS (Diluted)0.41+105.8%
- Gross Margin77.11%+2.5%
- EBITDA Margin14.14%-29.7%
- Operating Margin11.23%-32.4%
- Net Margin26.82%+127.9%
- ROE729.65%
SNWV Key Insights
SANUWAVE Health, Inc. (SNWV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 729.6%
- ✓Strong Piotroski F-Score: 7/9
- ✓Strong 5Y sales CAGR of 61.1%
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗High debt to equity ratio of 14.2x
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 51.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SNWV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SNWV Price & Volume
SANUWAVE Health, Inc. (SNWV) stock price & volume — 10-year historical chart
Loading chart...
SNWV Growth Metrics
SANUWAVE Health, Inc. (SNWV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years46.53%
5 Years61.12%
3 Years38.05%
TTM22.49%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM149.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM111.39%
Return on Capital
10 Years147.93%
5 Years147.93%
3 Years147.93%
Last Year136.04%
SNWV Recent Earnings
SANUWAVE Health, Inc. (SNWV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (50%)●Beat Revenue 2/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.17-21.4%
$0.14
Rev
$10M+0.2%
$10M
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.03-82.4%
$0.17
Rev
$13M+1.1%
$13M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.46+43.8%
$0.32
Rev
$11M-13.4%
$13M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.01+111.1%
$0.09
Rev
$10M-18.8%
$13M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.17vs $0.14-21.4% | $10Mvs $10M+0.2% |
| Q2 2026 | Mar 26, 2026 | $0.03vs $0.17-82.4% | $13Mvs $13M+1.1% |
| Q4 2025 | Nov 7, 2025 | $0.46vs $0.32+43.8% | $11Mvs $13M-13.4% |
| Q3 2025 | Aug 8, 2025 | $0.01vs $0.09+111.1% | $10Mvs $13M-18.8% |
Based on last 12 quarters of dataView full earnings history →
SNWV Peer Comparison
SANUWAVE Health, Inc. (SNWV) competitors in Aesthetics, dermatology, and wound care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MLSS | 32.7M | 0.37 | -5.30 | 3.99% | -51.3% | -166.28% | 0.36 | |
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ANIK | 193.24M | 14.42 | -18.97 | -5.91% | -9.52% | -7.74% | 0.17 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 CNMD | 1B | 32.58 | 21.58 | 5.16% | 4% | 5.4% | 0.81 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare SNWV vs Peers
SANUWAVE Health, Inc. (SNWV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNWV Income Statement
SANUWAVE Health, Inc. (SNWV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 738.53K | 1.85M | 1.03M | 4.06M | 13.01M | 16.74M | 20.4M | 32.63M | 44.05M | 44.33M |
Revenue Growth % | -46.33% | 150.51% | -44.39% | 294.37% | 220.68% | 28.69% | 21.84% | 59.99% | 34.98% | 22.49% |
Cost of Goods Sold | 241.97K | 693.66K | 538.92K | 1.16M | 4.99M | 4.33M | 6.04M | 8.08M | 10.08M | 10.78M |
COGS % of Revenue | 32.76% | 37.49% | 52.39% | 28.64% | 38.32% | 25.87% | 29.59% | 24.77% | 22.89% | - |
Gross Profit | 496.56K▲ 0% | 1.16M▲ 132.9% | 489.81K▼ 57.6% | 2.9M▲ 491.0% | 8.02M▲ 177.2% | 12.41M▲ 54.7% | 14.36M▲ 15.7% | 24.55M▲ 70.9% | 33.97M▲ 38.4% | 33.55M▲ 0% |
Gross Margin % | 67.24% | 62.51% | 47.61% | 71.36% | 61.68% | 74.13% | 70.41% | 75.23% | 77.11% | 75.68% |
Gross Profit Growth % | -38.77% | 132.88% | -57.64% | 491.05% | 177.17% | 54.67% | 15.73% | 70.93% | 38.37% | - |
Operating Expenses | 4.32M | 8.34M | 9.28M | 28.09M | 22.17M | 21.36M | 14.9M | 19.13M | 29.02M | 30.71M |
OpEx % of Revenue | 585.08% | 450.62% | 902.49% | 692.51% | 170.38% | 127.6% | 73.06% | 58.63% | 65.89% | - |
Selling, General & Admin | 3M | 7.33M | 8.03M | 18.88M | 20.28M | 20.03M | 13.57M | 17.67M | 26.79M | 28.44M |
SG&A % of Revenue | 406.81% | 396.35% | 780.68% | 465.44% | 155.89% | 119.64% | 66.54% | 54.15% | 60.82% | - |
Research & Development | 1.29M | 1.66M | 1.18M | 1.25M | 1.1M | 567K | 579K | 673K | 1.35M | 1.8M |
R&D % of Revenue | 175.01% | 89.93% | 114.89% | 30.71% | 8.46% | 3.39% | 2.84% | 2.06% | 3.07% | - |
Other Operating Expenses | 0 | 9.95K | 71.21K | 7.97M | 784K | 766K | 752K | 789K | 880K | 466K |
Operating Income | -3.82M▲ 0% | -7.18M▼ 87.7% | -8.79M▼ 22.5% | -25.2M▼ 186.5% | -14.14M▲ 43.9% | -8.95M▲ 36.7% | -540K▲ 94.0% | 5.42M▲ 1103.1% | 4.95M▼ 8.7% | 2.83M▲ 0% |
Operating Margin % | -517.85% | -388.11% | -854.87% | -621.15% | -108.7% | -53.47% | -2.65% | 16.6% | 11.23% | 6.4% |
Operating Income Growth % | -15.32% | -87.75% | -22.48% | -186.55% | 43.88% | 36.7% | 93.97% | 1103.15% | -8.71% | - |
EBITDA | -3.8M | -7.16M | -8.72M | -24.19M | -12.91M | -8M | 488K | 6.56M | 6.23M | 4.42M |
EBITDA Margin % | -514.59% | -386.9% | -847.95% | -596.2% | -99.2% | -47.78% | 2.39% | 20.11% | 14.14% | 9.98% |
EBITDA Growth % | -27.11% | -88.35% | -21.87% | -177.29% | 46.64% | 38.01% | 106.1% | 1244.67% | -5.09% | -48.88% |
D&A (Non-Cash Add-back) | 24.07K | 22.33K | 71.21K | 1.01M | 1.24M | 952K | 1.03M | 1.15M | 1.28M | 1.59M |
EBIT | -4.4M | -7.14M | -8.59M | -28.4M | -20.14M | 3.84M | -10.18M | -17.71M | 18.14M | 20.84M |
Net Interest Income | -1.14M | -4.5M | -1.84M | -2.54M | -7.09M | -14.13M | -15.62M | -13.64M | -6.25M | -4.94M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 1.14M | 4.5M | 1.84M | 2.54M | 7.09M | 14.13M | 15.62M | 13.64M | 6.25M | 4.94M |
Other Income/Expense | -1.71M | -4.45M | -1.64M | -5.74M | -13.09M | -1.34M | -25.26M | -36.76M | 6.95M | 13.3M |
Pretax Income | -5.54M▲ 0% | -11.63M▼ 110.0% | -10.43M▲ 10.3% | -30.94M▼ 196.6% | -27.23M▲ 12.0% | -10.29M▲ 62.2% | -25.8M▼ 150.7% | -31.34M▼ 21.5% | 11.9M▲ 138.0% | 16.14M▲ 0% |
Pretax Margin % | -749.86% | -628.7% | -1013.86% | -762.56% | -209.31% | -61.47% | -126.5% | -96.05% | 27.01% | 36.4% |
Income Tax | 0 | 45.01K | 0 | 0 | 28K | 2K | 4K | 27K | 86K | 86K |
Effective Tax Rate % | 0% | -0.39% | 0% | 0% | -0.1% | -0.02% | -0.02% | -0.09% | 0.72% | 0.53% |
Net Income | -5.54M▲ 0% | -11.63M▼ 110.0% | -10.43M▲ 10.3% | -30.94M▼ 196.6% | -27.26M▲ 11.9% | -10.29M▲ 62.2% | -25.81M▼ 150.7% | -31.37M▼ 21.6% | 11.81M▲ 137.7% | 16.05M▲ 0% |
Net Margin % | -749.86% | -628.7% | -1013.86% | -762.56% | -209.52% | -61.48% | -126.52% | -96.13% | 26.82% | 36.21% |
Net Income Growth % | 13.99% | -110.03% | 10.33% | -196.62% | 11.89% | 62.24% | -150.72% | -21.56% | 137.65% | 149.35% |
Net Income (Continuing) | -5.54M | -11.63M | -10.43M | -30.94M | -27.26M | -10.29M | -25.81M | -31.37M | 11.81M | 16.05M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -15.00▲ 0% | -29.17▼ 94.5% | -19.26▲ 34.0% | -30.68▼ 59.3% | -19.72▲ 35.7% | -7.02▲ 64.4% | -12.19▼ 73.6% | -7.03▲ 42.3% | 0.41▲ 105.8% | 1.87▲ 0% |
EPS Growth % | 33.33% | -94.45% | 33.95% | -59.26% | 35.72% | 64.4% | -73.65% | 42.33% | 105.83% | 111.39% |
EPS (Basic) | -15.00 | -29.17 | -19.26 | -30.68 | -19.72 | -7.02 | -12.19 | -7.03 | 1.38 | - |
Diluted Shares Outstanding | 370.24K | 398.77K | 541.44K | 1.01M | 1.38M | 1.47M | 2.12M | 4.46M | 9.08M | 8.59M |
Basic Shares Outstanding | 370.24K | 398.77K | 541.44K | 1.01M | 1.38M | 1.47M | 2.12M | 4.46M | 8.56M | 8.59M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SNWV Balance Sheet
SANUWAVE Health, Inc. (SNWV) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.2M | 1.08M | 2.5M | 7.93M | 4.4M | 6.62M | 9.78M | 18.4M | 24.63M | 23.96M |
Cash & Short-Term Investments | 730.18K | 364.55K | 1.76M | 2.44M | 619K | 1.15M | 1.8M | 10.24M | 11.96M | 10.78M |
Cash Only | 730.18K | 364.55K | 1.76M | 2.44M | 619K | 1.15M | 1.8M | 10.24M | 11.96M | 10.78M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 152.52K | 236K | 75.54K | 2.36M | 2.42M | 4.03M | 3.31M | 3.33M | 5.42M | 6M |
Days Sales Outstanding | 75.38 | 46.56 | 26.8 | 211.96 | 67.75 | 87.84 | 59.3 | 37.23 | 44.93 | 40.94 |
Inventory | 231.53K | 357.82K | 542.96K | 2.96M | 1.04M | 868K | 2.95M | 4.15M | 5.93M | 5.9M |
Days Inventory Outstanding | 349.25 | 188.28 | 367.73 | 928.52 | 76.13 | 73.15 | 178.48 | 187.33 | 214.83 | 207.91 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 570K | 1.72M | 682K | 1.31M | 1.27M |
Total Non-Current Assets | 74.29K | 94.25K | 877.63K | 15.1M | 14.22M | 13.25M | 12.63M | 11.72M | 12.72M | 13.14M |
Property, Plant & Equipment | 60.37K | 77.75K | 835.7K | 1.27M | 1.01M | 856K | 938K | 732K | 2.36M | 2.9M |
Fixed Asset Turnover | 12.23x | 23.79x | 1.23x | 3.20x | 12.86x | 19.56x | 21.75x | 44.58x | 18.65x | 17.85x |
Goodwill | 0 | 0 | 0 | 7.26M | 7.26M | 7.26M | 7.26M | 7.26M | 7.26M | 7.26M |
Intangible Assets | 0 | 0 | 0 | 6.54M | 5.84M | 5.14M | 4.43M | 3.73M | 3.03M | 2.92M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 13.92K | 16.49K | 41.93K | 28K | 106K | 0 | 0 | 0 | 68K | 58K |
Total Assets | 1.28M▲ 0% | 1.18M▼ 7.9% | 3.38M▲ 187.2% | 23.03M▲ 580.9% | 18.62M▼ 19.1% | 19.87M▲ 6.7% | 22.42M▲ 12.8% | 30.12M▲ 34.4% | 37.34M▲ 24.0% | 37.1M▲ 0% |
Asset Turnover | 0.58x | 1.57x | 0.30x | 0.18x | 0.70x | 0.84x | 0.91x | 1.08x | 1.18x | 1.24x |
Asset Growth % | 27.26% | -7.9% | 187.16% | 580.87% | -19.14% | 6.74% | 12.8% | 34.36% | 23.98% | 164.45% |
Total Current Liabilities | 11.16M | 16.49M | 12.42M | 36.17M | 56.26M | 60.22M | 64.75M | 42.34M | 17.85M | 18.3M |
Accounts Payable | 1.5M | 1.59M | 1.44M | 4.45M | 7.64M | 4.4M | 5.71M | 3.73M | 3.25M | 3.32M |
Days Payables Outstanding | 2.26K | 838.03 | 974.88 | 1.4K | 559.58 | 370.82 | 345.04 | 168.32 | 117.7 | 123.29 |
Short-Term Debt | 6.05M | 10.79M | 6.17M | 16.59M | 27.12M | 38.54M | 29.96M | 25.3M | 5.79M | 5.88M |
Deferred Revenue (Current) | 13.32K | 131.8K | 66.58K | 32K | 48K | 60K | 92K | 193K | 0 | 473K |
Other Current Liabilities | 2M | 3.63M | 1.61M | 11.42M | 13.97M | 8.45M | 19.18M | 10.67M | 8.8M | 9.1M |
Current Ratio | 0.11x | 0.07x | 0.20x | 0.22x | 0.08x | 0.11x | 0.15x | 0.43x | 1.38x | 1.31x |
Quick Ratio | 0.09x | 0.04x | 0.16x | 0.14x | 0.06x | 0.10x | 0.11x | 0.34x | 1.05x | 0.99x |
Cash Conversion Cycle | -1.83K | -603.19 | -580.35 | -258.58 | -415.69 | -209.83 | -107.26 | 56.24 | 142.06 | 125.57 |
Total Non-Current Liabilities | 0 | 46.74K | 1.03M | 571K | 1.31M | 668K | 839K | 491K | 17.88M | 16.95M |
Long-Term Debt | 0 | 0 | 0 | 143K | 875K | 0 | 0 | 0 | 16.32M | 1.29M |
Capital Lease Obligations | 0 | 0 | 457.02K | 391K | 118K | 438K | 492K | 191K | 854K | 2.74M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 28K | 28K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | -28K | 0 | 0 | 0 | 15.66M |
Total Liabilities | 11.16M | 16.53M | 13.45M | 36.74M | 57.58M | 60.88M | 65.59M | 42.84M | 35.72M | 35.26M |
Total Debt | 6.05M | 10.79M | 6.92M | 17.58M | 28.39M | 38.98M | 30.45M | 25.5M | 22.97M | 7.18M |
Net Debt | 5.32M | 10.43M | 5.16M | 15.14M | 27.77M | 37.82M | 28.66M | 15.26M | 11.01M | -3.6M |
Debt / Equity | - | - | - | - | - | - | - | - | 14.19x | 3.91x |
Debt / EBITDA | - | - | - | - | - | - | 62.41x | 3.89x | 3.69x | 1.62x |
Net Debt / EBITDA | - | - | - | - | - | - | 58.72x | 2.33x | 1.77x | -0.81x |
Interest Coverage | -3.86x | -1.59x | -4.68x | -11.18x | -2.84x | 0.27x | -0.65x | -1.30x | 2.91x | 4.22x |
Total Equity | -9.88M▲ 0% | -15.36M▼ 55.4% | -10.06M▲ 34.5% | -13.72M▼ 36.3% | -38.96M▼ 184.0% | -41.01M▼ 5.3% | -43.18M▼ 5.3% | -12.72M▲ 70.5% | 1.62M▲ 112.7% | 1.84M▲ 0% |
Equity Growth % | -42.96% | -55.41% | 34.47% | -36.31% | -183.99% | -5.27% | -5.29% | 70.55% | 112.73% | 381.19% |
Book Value per Share | -26.69 | -38.51 | -18.59 | -13.60 | -28.18 | -27.99 | -20.40 | -2.85 | 0.18 | 0.21 |
Total Shareholders' Equity | -9.88M | -15.36M | -10.06M | -13.72M | -38.96M | -41.01M | -43.18M | -12.72M | 1.62M | 1.84M |
Common Stock | 139.3K | 155.66K | 293.78K | 471K | 482K | 549K | 3K | 9K | 9K | 9K |
Retained Earnings | -104.97M | -116.6M | -125.75M | -156.69M | -183.95M | -194.24M | -220.05M | -251.42M | -242.69M | -244.12M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -43.78K | -62.87K | -62.23K | -62K | -73K | -67K | -111K | 10K | 10K | 10K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SNWV Cash Flow Statement
SANUWAVE Health, Inc. (SNWV) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.53M | -3.62M | -6.41M | -12.72M | -6.41M | -17.17M | -4.54M | 2.46M | 3.88M | 5.79M |
Operating CF Margin % | -207.03% | -195.73% | -623.17% | -313.48% | -49.26% | -102.55% | -22.25% | 7.52% | 8.8% | - |
Operating CF Growth % | 52.21% | -136.84% | -77.04% | -98.39% | 49.61% | -167.89% | 73.57% | 154.1% | 57.88% | 707.05% |
Net Income | -5.54M | -11.63M | -10.43M | -30.94M | -27.26M | -10.29M | -25.81M | -31.37M | 0 | 16.05M |
Depreciation & Amortization | 24.07K | 22.33K | 71.21K | 1.01M | 1.24M | 952K | 1.03M | 1.15M | 0 | 103K |
Stock-Based Compensation | 768.11K | 2.48M | 333.42K | 22K | 0 | 0 | 0 | 1.51M | 0 | -2.38M |
Deferred Taxes | 57.6K | -115.13K | -188.34K | 0 | 28K | 2K | 4K | 0 | 0 | 0 |
Other Non-Cash Items | 1.3M | 4.82M | 2.09M | 15.82M | 9.66M | -6.71M | 23.84M | 34.07M | 7.89M | 5.22M |
Working Capital Changes | 1.86M | 797.85K | 1.71M | 1.37M | 9.93M | -1.12M | -3.61M | -2.9M | -4.01M | -1.39M |
Change in Receivables | 250.68K | -22.5K | -8.6K | -2.58M | -395K | -1.75M | -53K | -486K | -2.3M | -2.34M |
Change in Inventory | -7.08K | -123.12K | -185.13K | -553K | 1.69M | -72K | -2.8M | -1.2M | -2.28M | -1.01M |
Change in Payables | 783.56K | 276.12K | -138.73K | 3.02M | 3.18M | -2.55M | 1.55M | -1.42M | -521K | -890K |
Cash from Investing | 0 | -42.89K | -53.94K | -20.05M | -529K | 332K | 21K | -490K | 3.43M | 3.44M |
Capital Expenditures | 0 | -42.89K | -53.94K | -53K | -529K | 1.02M | 0 | -490K | 0 | 4K |
CapEx % of Revenue | - | 2.32% | 5.24% | 1.31% | 4.07% | 6.1% | - | 1.5% | 4.41% | 0.01% |
Acquisitions | 0 | 0 | 0 | -20M | 0 | 332K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -1.02M | 21K | 0 | 3.43M | 3.43M |
Cash from Financing | 2.12M | 3.32M | 7.86M | 33.45M | 5.12M | 17.38M | 5.21M | 6.35M | -5.59M | -6.95M |
Debt Issued (Net) | 1.71M | 3.28M | 1.25M | 9.46M | 3.38M | 16.59M | 5.85M | -2.46M | -6.14M | -7.52M |
Equity Issued (Net) | 0 | 0 | 2.8M | 23.91M | 0 | 100K | 0 | 10.3M | 556K | 322K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 403.07K | 40.73K | 3.81M | 81K | 1.74M | 695K | -639K | -1.49M | 0 | 253K |
Net Change in Cash | 596.61K▲ 0% | -365.63K▼ 161.3% | 1.4M▲ 481.8% | 676K▼ 51.6% | -1.82M▼ 368.9% | 534K▲ 129.4% | 644K▲ 20.6% | 8.44M▲ 1210.6% | 1.72M▼ 79.6% | 2.28M▲ 0% |
Free Cash Flow | -1.53M▲ 0% | -3.66M▼ 139.6% | -6.46M▼ 76.4% | -12.77M▼ 97.5% | -6.94M▲ 45.7% | -16.15M▼ 132.7% | -4.54M▲ 71.9% | 1.97M▲ 143.3% | 1.93M▼ 1.6% | 5.86M▲ 0% |
FCF Margin % | -207.03% | -198.05% | -628.42% | -314.79% | -53.33% | -96.45% | -22.25% | 6.02% | 4.39% | 13.23% |
FCF Growth % | 52.37% | -139.64% | -76.44% | -97.55% | 45.67% | -132.73% | 71.9% | 143.3% | -1.58% | 937.57% |
FCF per Share | -4.13 | -9.19 | -11.94 | -12.67 | -5.02 | -11.02 | -2.14 | 0.44 | 0.21 | 0.68 |
FCF Conversion (FCF/Net Income) | 0.28x | 0.31x | 0.61x | 0.41x | 0.24x | 1.67x | 0.18x | -0.08x | 0.33x | 0.37x |
Interest Paid | 0 | 0 | 0 | 436K | 2.58M | 0 | 1.96M | 4.31M | 3.74M | 1.14M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27K | 0 |
SNWV Key Ratios
SANUWAVE Health, Inc. (SNWV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | - | - | - | - | - | 729.65% | -450.56% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | 159.82% | 48.89% | 30.96% |
Gross Margin | 67.24% | 62.51% | 47.61% | 71.36% | 61.68% | 74.13% | 70.41% | 75.23% | 77.11% | 75.68% |
Net Margin | -749.86% | -628.7% | -1013.86% | -762.56% | -209.52% | -61.48% | -126.52% | -96.13% | 26.82% | 36.21% |
Debt / Equity | - | - | - | - | - | - | - | - | 14.19x | 3.91x |
Interest Coverage | -3.86x | -1.59x | -4.68x | -11.18x | -2.84x | 0.27x | -0.65x | -1.30x | 2.91x | 4.22x |
FCF Conversion | 0.28x | 0.31x | 0.61x | 0.41x | 0.24x | 1.67x | 0.18x | -0.08x | 0.33x | 0.37x |
Revenue Growth | -46.33% | 150.51% | -44.39% | 294.37% | 220.68% | 28.69% | 21.84% | 59.99% | 34.98% | 22.49% |
Related:SNWV Dividend History·SNWV Revenue History·SNWV Price History·SNWV P/E History·SNWV Financial Ratios·SNWV Institutional Holders
SNWV SEC Filings & Documents
SANUWAVE Health, Inc. (SNWV) SEC filings — annual & quarterly reports (10-K, 10-Q)
SNWV Frequently Asked Questions
SANUWAVE Health, Inc. (SNWV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
SANUWAVE Health, Inc. (SNWV) reported $44.3M in revenue for fiscal year 2025.
SANUWAVE Health, Inc. (SNWV) grew revenue by 35.0% over the past year. This is strong growth.
Yes, SANUWAVE Health, Inc. (SNWV) is profitable, generating $16.1M in net income for fiscal year 2025 (26.8% net margin).
Dividend & Returns
SANUWAVE Health, Inc. (SNWV) has a return on equity (ROE) of 729.6%. This is excellent, indicating efficient use of shareholder capital.
SANUWAVE Health, Inc. (SNWV) generated $5.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.